In this consortium

we have the ability to achieve ground-breaking progress and Establish a multimodal imaging workflow based on a new PET tracer and embracing structural and functional MRI methods to yield a tool that sensitively and specifically detects αSYN pathology and associated changes Test this multimodal, molecular neuroimaging methodology in animal models with regard to its potential for diagnosis, monitoring the natural disease course and response to therapy, as well as guide and optimize therapeutic interventions.

Translate the workflow including the therapeutic modality (i.e. immunotherapy with PD01A, NCT01568099) to the clinical setting.